XXII

22nd Century Group Inc (Ticker: XXII) is a biopharmaceutical and agricultural innovator dedicated to tobacco harm reduction and the development of advanced plant-based solutions. The company focuses on genetic engineering techniques to produce low-nicotine tobacco products, aimed at decreasing addiction and enhancing public health. Beyond its groundbreaking work in the tobacco sector, 22nd Century is also making strides in the hemp and cannabis industries, thereby strategically aligning itself with the expanding legal cannabis market. With its emphasis on scientific rigor and adherence to regulatory standards, 22nd Century is well-positioned to leverage transformative opportunities within both tobacco and cannabis segments, making it a compelling prospect for institutional investors.